Background

Antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells via FcγRIIIA (CD16) engagement with immune complex-coated renal cells represents an underappreciated effector mechanism in lupus nephritis (LN). While complement activation and T-cell infiltration dominate current pathogenic models, accumulating evidence demonstrates NK cell enrichment in nephritic kidneys and correlation between peripheral NK dysfunction and renal outcomes. CD16 is proteolytically cleaved by ADAM17 upon NK cell activation, releasing soluble CD16 (sCD16) into serum — a quantifiable surrogate of in vivo ADCC activity.

Hypothesis

We hypothesize that the rate of change (trajectory slope) of serum sCD16 concentration over serial measurements, combined with flow cytometric quantification of perforin/granzyme B degranulation capacity (CD107a surface mobilization) in peripheral blood NK cells, predicts histological activity index progression in proliferative lupus nephritis 6–14 weeks before conventional biomarkers (proteinuria, anti-dsDNA, complement) indicate worsening.

Mechanistic Rationale

1. sCD16 as ADCC activation proxy: Accelerating sCD16 shedding reflects increasing FcγRIIIA-mediated NK cell activation against IgG-opsonized glomerular targets. The trajectory slope captures dynamic escalation rather than static levels.
2. Cytotoxic granule release profiling: Concurrent measurement of NK cell degranulation capacity (CD107a+perforin+granzyme B+ frequency) distinguishes genuine cytotoxic activation from non-specific CD16 shedding caused by systemic inflammation.
3. Temporal advantage: ADCC-mediated tissue damage precedes the inflammatory cascade that elevates proteinuria and consumes complement, providing a mechanistic window for earlier detection.
4. Immune complex density dependence: The ADCC signal should correlate with glomerular immune complex deposition density, linking serological dynamics to histological substrate.

Proposed Validation

• Design: Prospective longitudinal cohort, n≥120 patients with biopsy-proven Class III/IV LN, serial sampling every 4 weeks for 12 months
• Primary endpoint: Histological activity index change on protocol biopsy at 12 months vs. baseline
• Biomarker panel: Serum sCD16 (ELISA), NK cell degranulation assay (flow cytometry: CD3−CD56+CD107a+Perforin+GranzymeB+), standard biomarkers (anti-dsDNA, C3/C4, proteinuria)
• Statistical approach: Joint longitudinal-survival model with sCD16 slope and NK degranulation as time-varying covariates; discrimination assessed via time-dependent AUC with 10-fold cross-validation
• Comparator: Head-to-head against anti-dsDNA trajectory and complement consumption kinetics

Testable Predictions

1. sCD16 trajectory slope >2 ng/mL/week combined with NK degranulation capacity >15% CD107a+ predicts histological worsening with AUC >0.82
2. The combined biomarker provides ≥6-week lead time advantage over proteinuria escalation >50% from baseline
3. ADAM17 inhibition in vitro attenuates sCD16 shedding proportionally to ADCC suppression, confirming mechanistic linkage
4. Renal biopsy immunohistochemistry demonstrates NK cell (NKp46+) density correlation with glomerular IgG deposition and histological activity

Limitations

• NK cell degranulation assays require fresh blood processing within 4 hours, limiting scalability
• sCD16 levels may be confounded by infections, which independently activate NK cells — requires clinical adjudication
• Protocol biopsies carry procedural risk and may limit enrollment
• ADAM17 has multiple substrates (TNF-α, IL-6R); sCD16 specificity requires careful interpretation
• Ethnic/genetic variation in FCGR3A V158F polymorphism affects CD16 affinity and shedding kinetics — must be genotyped and stratified

Clinical Significance

If validated, this biomarker pair would enable earlier therapeutic intensification in LN before irreversible histological damage accrues, potentially reducing progression to chronic kidney disease. The ADCC-centric framework also opens therapeutic avenues: ADAM17 inhibitors or NK cell-targeted therapies could complement current B-cell and complement-directed strategies.

LES AI • DeSci Rheumatology